|
TRIM2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.61930469033678E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.5767947471661E-11 |
| Normal-vs-Stage2 |
2.45169999999462E-05 |
| Normal-vs-Stage3 |
2.19935181178244E-13 |
| Normal-vs-Stage4 |
5.44009282066327E-15 |
| Stage1-vs-Stage2 |
4.021800E-02 |
| Stage1-vs-Stage3 |
8.682300E-02 |
| Stage1-vs-Stage4 |
1.022900E-04 |
| Stage2-vs-Stage3 |
7.363600E-03 |
| Stage2-vs-Stage4 |
5.99399999999806E-05 |
| Stage3-vs-Stage4 |
9.531500E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
7.23690000037358E-07 |
| Normal-vs-Asian |
3.88239995707806E-10 |
| Caucasian-vs-AfricanAmerican |
9.965000E-01 |
| Caucasian-vs-Asian |
8.093600E-01 |
| AfricanAmerican-vs-Asian |
8.671800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.68385355343071E-13 |
| Normal-vs-Female |
1.62581059726108E-12 |
| Male-vs-Female |
2.922500E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.69875224997895E-12 |
| Normal-vs-Age(41-60Yrs) |
2.22044604925031E-14 |
| Normal-vs-Age(61-80Yrs) |
1.30050414881566E-11 |
| Normal-vs-Age(81-100Yrs) |
8.48850000000345E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.656400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.216400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.486200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.881200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.810600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.260600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.407400E-04 |
| Classical-VS-Follicular |
8.20980000000304E-05 |
| Classical-VS-Other |
8.612000E-01 |
| Classical-VS-Normal |
1.19160237233018E-11 |
| Tall-VS-Follicular |
2.64230004543009E-09 |
| Tall-VS-Other |
2.581800E-01 |
| Tall-VS-Normal |
3.10862446895044E-15 |
| Follicular-VS-Other |
2.616200E-01 |
| Follicular-VS-Normal |
2.40379999999485E-05 |
| Other-VS-Normal |
4.076200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.27809984817873E-10 |
| Normal-vs-N1 |
1.62858615482264E-12 |
| N0-vs-N1 |
1.51572000000044E-05 |
|
|
